ROCKVILLE, Md., March 29,
2024 /PRNewswire/ -- Revolutionary genomic research
by Genzeva, LumaGene, RYLTI, Brigham & Women's Hospital of
Harvard University, and QIAGEN Digital
Insights applied an innovative use of multiomics and biomimetic
digital twins to unveil new DNA variants associated with the
development of endometrial related disorders. This study marks a
significant leap forward in understanding the molecular mechanisms
of endometrial-related disorders.
The study was highlighted in a paper
published today in the Journal of Molecular Diagnostics.
In a paper published today in the Journal of Molecular
Diagnostics, the study led by geneticist Dr. William G. Kearns, Co-founder, CEO and Chief
Scientific Officer of Genzeva and LumaGene, employed cutting-edge
methodologies incorporating clinical exome sequencing,
phenotype-driven variant analysis, and RYLTI's Knowledge
Engineering (RKE) Biomimetic AI Platform and Digital Twin
Ecosystem, to analyze patient samples with endometriosis. This
unprecedented multidimensional approach uncovered novel insights by
analyzing hidden "dark" data, which allowed the team to identify
eight pathogenic mutations and four variants of unknown clinical
significance (VUSs) relevant to this disorder.
In addition to identifying pathogenic DNA variants the research
also identiļ¬ed four VUSs potentially associated with the
development of endometrial-related disorders. One VUS identified in
the MUC20 gene was present across all patient samples and
could be a potential biomarker for diagnostics. The other
identified VUSs in genes USP17L1, FAM66B, and
DEFB109B all mapped to the short arm of chromosome 8. The
expression of the DEFB109B and FAM66B genes are
regulated by the same gene enhancer.
The paper, "The Application of Knowledge Engineering via the use
of a Biomimetic Digital Twin Ecosystem, Phenotype Driven Variant
Analysis, and Exome Sequencing to Understand the Molecular
Mechanisms of Disease," was authored by Kearns and
collaborators Dr. J. Georgios
Stamoulis (QIAGEN Digital Insights), Joseph Glick and Lawrence Baisch (RYLTI BioPharma); Andrew Benner, Dalton
Brough, Dr. Luke Du (Genzeva); Dr. Bradford Wilson (IndyGeneUS AI); Laura Kearns (Genzeva and LumaGene);
Nicholas Ng, Maya Seshan, and Dr. Raymond Anchan (Brigham and Women's Hospital,
Harvard University).
"This landmark study demonstrated a way to combine omics
and a digital twin ecosystem to understand the molecular mechanism
of disease better. By incorporating Genzeva's multiomics platform,
QIAGEN's Digital Insight, and RYLTI's pioneering biomimetic AI
platform for genomic analyses we uncovered hidden dark data with
insights that may never have been achievable before. The
possibility to redefine this scientific approach promises a new
horizon in many fields of research, and the biotech industry
eagerly anticipates the impact of these innovative techniques on
future discoveries and therapeutic interventions," commented Dr.
Kearns.
In January, Life Sciences Review Magazine awarded
RYLTI Top Biomimetic AI Platform of 2024 for its
biomimetic AI digital twin ecosystem innovation, hailing the
technology for opening new doors to discovery and accelerating the
innovation process.
Dr. Ray Anchan, Asst. Professor
Harvard Medical School/Co-Director,
Brigham, and Women's Hospital Center for Endometriosis, said: "The
computational capacity of knowledge engineering using a biomimetic
digital twin ecosystem provides a unique opportunity to efficiently
identify novel and unique DNA variants in various disease processes
that could prove useful for developing new targeted therapies."
"The NAS has described the importance of using digital twins in
biomedical research, which requires a toolset without limitations
or bias for effective discovery and validation," said Joseph Glick, an award-winning biomimetic AI
pioneer and Co-founder/Chief Innovation Officer of RYLTI. "This new
innovative omics method incorporating phenotype ranking algorithms
with digital twins demonstrates the potential to enhance the drug
discovery process with the inclusion of data, enabling improved
decision making, expedited development timelines, refined target
identification, and reduced risks."
"This exciting breakthrough with use of the first biomimetic
digital twins comes at a very exciting time for us, not only in
advanced genomic research, but across biopharma and in other
sectors," said Peter Fiorillo,
Co-founder and CEO of RYLTI.
About GENZEVA
GENZEVA is a leading molecular diagnostic laboratory utilizing
advanced multiomics and patent-pending technology solutions. It
provides services to healthcare research organizations worldwide,
clinicians, and referring laboratories. For more information, visit
www.genzeva.com.
About RYLTI BioPharma
RYLTI is the architect behind its revolutionary RYAILITI
Knowledge Engineering (RKE) Biomimetic AI Digital Twin Platform and
innovative solutions for a variety of industries, including the
pharmaceutical, biotechnology, renewable energy,
telecommunications, financial services, and technology industries,
among other sectors. For more information, visit
www.ryaliiti.com.
For media inquiries, please contact:
Peter Fiorillo
|
Dr. William G.
Kearns
|
CEO RYLTI BioPharma
Inc
|
CEO and CSO
Genzeva and LumaGene
|
pfiorillo@rylti.com
|
wgkearns@genzeva.com
|
(631) 806-2108
|
(301)
366-1666
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/first-study-using-biomimetic-ai-digital-twins-and-multiomics-in-genetics-research-302103336.html
SOURCE RYLTI